Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. News
  7. Summary
    ABBV   US00287Y1091


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AbbVie CEO defends Pharmacyclics deal to sceptical investors

03/05/2015 | 05:30pm EDT

NEW YORK (Reuters) - AbbVie Inc chief Richard Gonzalez fought two other drugmakers to "the bitter end" to buy Pharmacyclics Inc (>> Pharmacyclics, Inc.) for its hot-selling Imbruvica cancer drug, but may have a harder time convincing investors it is worth $21 billion.

NEW YORK (Reuters) - AbbVie Inc chief Richard Gonzalez fought two other drugmakers to "the bitter end" to buy Pharmacyclics Inc (>> Pharmacyclics, Inc.) for its hot-selling Imbruvica cancer drug, but may have a harder time convincing investors it is worth $21 billion.

Gonzalez, who took over as chief executive in early 2013, has come under closer scrutiny after AbbVie (>> AbbVie Inc) abandoned a $55 billion deal to purchase Shire Plc (>> Shire PLC) last year due to new U.S. tax rules that wiped out much of the deal's rationale.

Since then, some shareholders have questioned how the company will protect its best-selling drug Humira, for arthritis, against new rivals when it loses patent protection in late 2016. Others have criticized steep discounts AbbVie has offered on its new hepatitis C drug, to win coverage from U.S. health insurers.

AbbVie announced the Pharmacyclics deal late on Wednesday, saying it would hurt company earnings this year and next, then boost profits from 2017 and beyond. Company shares fell almost 6 percent.

"AbbVie is taking a hit today because of the dilution and because they look a little desperate to do a deal," said Chris Pultz, portfolio manager for Kellner Merger Fund, an arbitrage fund that took a stake in Pharmacyclics on Thursday. "AbbVie lost a little credibility" by paying top dollar for Pharmacyclics, he said.

In a conference call, Gonzalez said Imbruvica will eventually bring the company $7 billion in annual sales - ahead of some Wall Street estimates - and boost a pipeline of experimental cancer drugs that AbbVie hopes will be worth more than $8 billion in combined sales each year.

That made it worth fighting for Pharmacyclics, he said. Johnson & Johnson (>> Johnson & Johnson), a partner in developing Imbruvica, was widely reported as a second bidder, while the identity of a third suitor has not been confirmed.

"It was a highly competitive multi-round process," Gonzalez told Reuters. "We bid against two large, sophisticated pharmaceutical companies. And when disclosures come out, you'll see the spread (between bids). I don't think we'll look embarrassed."

Gonzalez said AbbVie became interested in Pharmacyclics about 18 months ago, but didn't actively pursue a deal until being informed in recent months that AbbVie was on a short list of favoured suitors.

Gonzalez met with Pharmacyclics CEO Bob Duggan in January, followed by three other trips to California's Bay Area, where the company is based. Bidding began about two weeks ago, he said.

Gonzalez said Imbruvica would make AbbVie less reliant on Humira, a $13-billion-a-year blockbuster. AbbVie said it has also sought U.S. and European marketing approvals for an improved formulation that could battle cheaper biosimilar forms of Humira.

"It's a fundamental change in the formulation of Humira," Gonzalez said in an interview. "I wouldn't describe it as a tweak." Asked if AbbVie intends to switch over current Humira patients to the new formulation, Gonzalez said such a strategy would make sense.

Citigroup analyst Andrew Baum wrote in a research note that the new version of Humira would likely have an auto-injector that would cause less pain than regular needles and might not need refrigeration. Such improvements, he said, could lead 20 percent of current Humira patients to switch to the new product.

(Reporting by Ransdell Pierson; Editing by Michele Gershberg and Leslie Adler)

By Ransdell Pierson

Stocks treated in this article : Johnson & Johnson, Pharmacyclics, Inc., Shire PLC, AbbVie Inc

© Reuters 2015
Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE INC. -1.01% 115.08 Delayed Quote.7.40%
BEST INC. 0.00% 1.06 Delayed Quote.-48.04%
JOHNSON & JOHNSON -0.59% 173.36 Delayed Quote.10.15%
MADE 0.00% 8.75 Real-time Quote.50.86%
SHIRE PLC 0.00%End-of-day quote.0.00%
SWITCH, INC. -1.83% 20.35 Delayed Quote.24.31%
THE LEAD CO., INC. 8.59% 708 End-of-day quote.-15.71%
All news about ABBVIE INC.
08/04ABBVIE : Says Medical Journal Shows Rinvoq as Better Atopic Dermatitis Treatment..
08/04ABBVIE : JAMA Dermatology Publishes Data Showing RINVOQ® (upadacitinib) Achieved..
08/02ABBVIE : JPMorgan Adjusts AbbVie Price Target to $140 From $135, Maintains Overw..
08/02ABBVIE : Goldman Sachs Adjusts AbbVie Price Target to $112 From $115, Maintains ..
08/02ABBVIE : Reports Second-Quarter 2021 Financial Results
08/02ABBVIE : Barclays Adjusts AbbVie's Price Target to $112 From $105, Keeps Equal-W..
08/02ABBVIE : Mizuho Securities Adjusts AbbVie's Price Target to $131 From $128, Main..
07/30Health Care Down As Traders Seek Out Inflation-Linked Sectors -- Health Care ..
07/30ABBVIE : Allergan - FDA Approves Expanded BOTOX Label to Include Eight New Muscl..
More news
Financials (USD)
Sales 2021 56 263 M - -
Net income 2021 12 810 M - -
Net Debt 2021 65 178 M - -
P/E ratio 2021 15,4x
Yield 2021 4,46%
Capitalization 203 B 203 B -
EV / Sales 2021 4,77x
EV / Sales 2022 4,29x
Nbr of Employees 48 000
Free-Float 98,0%
Duration : Period :
AbbVie Inc. Technical Analysis Chart | ABBV | US00287Y1091 | MarketScreener
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 115,08 $
Average target price 125,56 $
Spread / Average Target 9,10%
EPS Revisions
Managers and Directors
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman-Management Board & President
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Azita Saleki-Gerhardt Executive Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ABBVIE INC.7.40%203 367
JOHNSON & JOHNSON10.15%459 079
ROCHE HOLDING AG14.16%340 492
PFIZER, INC.22.77%255 703
NOVARTIS AG-0.20%224 638